Arsanis has successfully raised capital from top-tier life science investors OrbiMed, Polaris Ventures, SV Life Sciences, NeoMed, EMBL Ventures, The Bill & Melinda Gates Foundation, and GV, securing $85M since 2010.



Arsanis has also entered into multiple collaborations with leading industry, academic, and clinical research groups, building relationships with global leaders in the fields of antibody discovery and infectious diseases.

Arsanis’ lead clinical candidate, ASN100, and human mAbs in several pre-clinical programs (ASN400 and ASN500), were discovered in collaboration with Adimab, LLC, utilizing their industry premier human antibody discovery and optimization platform.